Scoop: Pfizer once again takes out the budget ax, lopping off 150 R&D staffers and 5 preclinical biosimilar drugs
Pfizer is taking the ax to its preclinical R&D group for biosimilars in a move designed to end — at least for now — any new expansion of the pipeline for knockoffs.
After messages began to pop up on social media from staffers getting the ax, a Pfizer spokesperson confirmed to me that the company is cutting 150 staffers at 2 sites, in Lake Forest, IL and Chennai, India and ending development of 5 preclinical programs.
Basic subscription required
Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.